We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers incl... Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. Show more
[212Pb]VMT-Ξ±-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of nine patients had durable control of...
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.Β (βPerspectiveβ or the βCompanyβ) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -5.42 | -60.6942889138 | 8.93 | 8.93 | 2.94 | 3674767 | 4.30211493 | CS |
4 | -8.42 | -70.5783738474 | 11.93 | 12.9 | 2.94 | 1423584 | 6.71255337 | CS |
12 | -12.03 | -77.4131274131 | 15.54 | 16.31 | 2.94 | 1115838 | 10.4928361 | CS |
26 | -12.29 | -77.7848101266 | 15.8 | 16.7 | 2.94 | 1729685 | 12.29672067 | CS |
52 | 0.91 | 35 | 2.6 | 19.05 | 2.28 | 2533014 | 12.3716851 | CS |
156 | -0.253 | -6.72335902206 | 3.763 | 19.05 | 2.05 | 1727583 | 11.07929074 | CS |
260 | -0.253 | -6.72335902206 | 3.763 | 19.05 | 2.05 | 1727583 | 11.07929074 | CS |
Symbol | Price | Vol. |
---|---|---|
MSTZT Rex 2X Inverse MSTR Daily Target ETF | US$ 0.9467 (-11.52%) | 808.14M |
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3.22 (6.62%) | 56.76M |
FXIiShares China Large Cap | US$ 29.69 (-2.17%) | 54.61M |
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 28.49 (0.00%) | 51.86M |
SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 6.035 (-0.74%) | 49.97M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions